226 related articles for article (PubMed ID: 32707866)
21. Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib.
Barbagallo I; Giallongo C; Volti GL; Distefano A; Camiolo G; Raffaele M; Salerno L; Pittalà V; Sorrenti V; Avola R; Di Rosa M; Vanella L; Di Raimondo F; Tibullo D
Mol Neurobiol; 2019 Feb; 56(2):1451-1460. PubMed ID: 29948946
[TBL] [Abstract][Full Text] [Related]
22. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
[TBL] [Abstract][Full Text] [Related]
23. Implications and hidden toxicity of cardiometabolic syndrome and early-stage heart failure in carfilzomib-induced cardiotoxicity.
Efentakis P; Varela A; Lamprou S; Papanagnou ED; Chatzistefanou M; Christodoulou A; Davos CH; Gavriatopoulou M; Trougakos I; Dimopoulos MA; Terpos E; Andreadou I
Br J Pharmacol; 2024 Apr; ():. PubMed ID: 38679957
[TBL] [Abstract][Full Text] [Related]
24. A possible antineoplastic potential of selective, irreversible proteasome inhibitor, carfilzomib on chemically induced hepatocarcinogenesis in rats.
Mansour MA; Aljoufi MA; Al-Hosaini K; Al-Rikabi AC; Nagi MN
J Biochem Mol Toxicol; 2014 Sep; 28(9):400-6. PubMed ID: 24861196
[TBL] [Abstract][Full Text] [Related]
25. Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats.
Al-Harbi NO
Toxicol Mech Methods; 2016; 26(3):189-95. PubMed ID: 26899300
[TBL] [Abstract][Full Text] [Related]
26. TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing.
Reale A; Khong T; Mithraprabhu S; Savvidou I; Hocking J; Bergin K; Ramachandran M; Chen M; Dammacco F; Ria R; Silvestris F; Vacca A; Reynolds J; Spencer A
Leuk Lymphoma; 2021 Feb; 62(2):337-347. PubMed ID: 33131357
[TBL] [Abstract][Full Text] [Related]
27. Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.
Gao M; Gao L; Tao Y; Hou J; Yang G; Wu X; Xu H; Tompkins VS; Han Y; Wu H; Zhan F; Shi J
Acta Biochim Biophys Sin (Shanghai); 2014 Jun; 46(6):484-91. PubMed ID: 24801128
[TBL] [Abstract][Full Text] [Related]
28. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Besse L; Kraus M; Besse A; Driessen C; Tarantino I
Sci Rep; 2023 Mar; 13(1):4411. PubMed ID: 36932175
[TBL] [Abstract][Full Text] [Related]
29. Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.
Nabissi M; Morelli MB; Offidani M; Amantini C; Gentili S; Soriani A; Cardinali C; Leoni P; Santoni G
Oncotarget; 2016 Nov; 7(47):77543-77557. PubMed ID: 27769052
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib.
Thakur S; Ruan Y; Jayanthan A; Boklan J; Narendran A
Curr Cancer Drug Targets; 2021; 21(9):804-811. PubMed ID: 33949932
[TBL] [Abstract][Full Text] [Related]
31.
Pokorna Z; Jirkovsky E; Hlavackova M; Jansova H; Jirkovska A; Lencova-Popelova O; Brazdova P; Kubes J; Sotakova-Kasparova D; Mazurova Y; Adamcova M; Vostatkova L; Holzerova K; Kolar F; Simunek T; Sterba M
Clin Sci (Lond); 2019 Aug; 133(16):1827-1844. PubMed ID: 31409729
[TBL] [Abstract][Full Text] [Related]
32. Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity.
Reichel D; Lee MJ; Lee W; Kim KB; Bae Y
Ther Deliv; 2016 Oct; 7(10):665-681. PubMed ID: 27790952
[TBL] [Abstract][Full Text] [Related]
33. Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.
Park JE; Park J; Jun Y; Oh Y; Ryoo G; Jeong YS; Gadalla HH; Min JS; Jo JH; Song MG; Kang KW; Bae SK; Yeo Y; Lee W
J Control Release; 2019 May; 302():148-159. PubMed ID: 30954620
[TBL] [Abstract][Full Text] [Related]
34. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
35. Sustained Delivery of Carfilzomib by Tannic Acid-Based Nanocapsules Helps Develop Antitumor Immunity.
Taha MS; Cresswell GM; Park J; Lee W; Ratliff TL; Yeo Y
Nano Lett; 2019 Nov; 19(11):8333-8341. PubMed ID: 31657935
[TBL] [Abstract][Full Text] [Related]
36. A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo.
Zhang C; Wang X; Cheng R; Zhong Z
Biomacromolecules; 2020 Jun; 21(6):2049-2059. PubMed ID: 32338875
[TBL] [Abstract][Full Text] [Related]
37. Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.
Lamothe B; Wierda WG; Keating MJ; Gandhi V
Clin Cancer Res; 2016 Sep; 22(18):4712-26. PubMed ID: 27026200
[TBL] [Abstract][Full Text] [Related]
38. Chemo-Phototherapy with Carfilzomib-Encapsulated TiN Nanoshells Suppressing Tumor Growth and Lymphatic Metastasis.
Wu X; Wang L; Xu YN; Chen JL; Luo KQ; Yuan MH; Li J; Yuan G; Gu ZY; Jia XH; Chen X; Zhu XM; Jiang R
Small; 2022 Jul; 18(29):e2200522. PubMed ID: 35748183
[TBL] [Abstract][Full Text] [Related]
39. Antibody-Mediated Nanodrug of Proteasome Inhibitor Carfilzomib Boosts the Treatment of Multiple Myeloma.
Chen R; Yang J; Mao Y; Zhao X; Cheng R; Deng C; Zhong Z
Biomacromolecules; 2023 Nov; 24(11):5371-5380. PubMed ID: 37801632
[TBL] [Abstract][Full Text] [Related]
40. Carfilzomib.
Engelhardt M; Szymaniak-Vits M; Ajayi S; Dold SM; Müller SJ; Scheubeck S; Wäsch R
Recent Results Cancer Res; 2018; 212():265-283. PubMed ID: 30069635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
